title: Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females.
authors.forename: Laia
authors.initials: L
authors.lastname: Paré
authors.forename: Juliana
authors.initials: J
authors.lastname: Salazar
authors.forename: Elisabeth
authors.initials: E
authors.lastname: del Rio
authors.forename: Montserrat
authors.initials: M
authors.lastname: Baiget
authors.forename: Albert
authors.initials: A
authors.lastname: Altés
authors.forename: Eugenio
authors.initials: E
authors.lastname: Marcuello
authors.forename: David
authors.initials: D
authors.lastname: Paez
authors.forename: Agustí
authors.initials: A
authors.lastname: Barnadas
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D015331:Cohort Studies; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D005472:Fluorouracil